New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains

Marianna Nalli, Jorge I Armijos Rivera, Domiziana Masci, Antonio Coluccia, Roger Badia, Eva Riveira-Muñoz, Alessandro Brambilla, Elisabetta Cinquina, Ombretta Turriziani, Francesca Falasca, Myriam Catalano, Cristina Limatola, José A Esté, Giovanni Maga, Romano Silvestri, Emmanuele Crespan, Giuseppe La Regina

Research output: Contribution to journalArticlepeer-review

5 Downloads (Pure)

Abstract

We designed and synthesized 21 new indolylarylsulfones (IASs) as new HIV-1 NNRTIs. Among these, IAS 12 exhibited a remarkable antiviral activity against single and double mutants (K103N EC50 = <0.7 nM; Y181C EC50 = <0.7 nM; Y188L EC50 = 21.3 nM; K103N-Y181C EC50 = 6.2 nM), resulting equally or more active than previuosly reported IAS 6 and some approved anti-HIV-1 drugs. Docking and molecular dynamics simulations of compound 12 in complex with WT, Y181C, Y188L, K103N and K103N-Y181C RTs clarified a general binding mode that was consistent with biological results. Kinetic experiments disclosed that derivative 12 preferentially binds WT and K103N-Y181C RTs to binary and ternary complexes, respectively.

Original languageEnglish
Pages (from-to)112696
JournalEuropean Journal of Medicinal Chemistry
Volume208
DOIs
Publication statusE-pub ahead of print - Aug 11 2020

Fingerprint Dive into the research topics of 'New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains'. Together they form a unique fingerprint.

Cite this